Nissen: ACCME should be abolished

Share this article:
The ACCME is a toothless watchdog and should be abolished, said Cleveland Clinic's Dr. Steven Nissen at a Senate Committee on Aging hearing.

The accrediting body is “uninterested or incapable” of enforcing its own rules, said Nissen, who groused that he had written letters to ACCME complaining of bias in continuing education but hadn't received so much as an acknowledgment. “Whatever ACCME is doing is ineffective,” said Nissen. “We need ACCME to go away and we need to replace it with something else.” He said industry-funded CME is a huge driver of healthcare costs, estimating that the government could save $900 billion over 10 years on unnecessary prescribing of branded drugs—in part through curbing bias in continuing education. “That's one of the ways we can pay for healthcare reform,” said Nissen.

ACCME chief Dr. Murray Kopelow defended his organization at the hearing, detailing tougher guidelines that the group has instituted in recent months and saying that the lax practices described by critics “is in another time and another place.” But conflict-of-interest hawks far outnumbered defenders of the CME profession, and the event had the feel of a pile-on, as speaker after speaker painted a bleak picture of a CME enterprise that comingles marketing and education, and senators questioned the value of commercial support.

Lew Morris, general counsel at the Department of Health and Human Services' Office of the Inspector General, suggested that eliminating commercial support altogether was “appealing for its purity and simplicity,” and said drug and device companies must separate grant-writing functions from sales and marketing and eliminate any control over speakers and content—seemingly oblivious to the fact that they have already done so.

Eric Campbell, of Harvard Medical School and the Institute of Medicine conflict of interest committee, said “the current system of funding is unacceptable and should not continue.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.